Literature DB >> 25203723

Brain distribution pharmacokinetics and integrated pharmacokinetics of Panax Notoginsenoside R1, Ginsenosides Rg1, Rb1, Re and Rd in rats after intranasal administration of Panax Notoginseng Saponins assessed by UPLC/MS/MS.

Qingli Guo1, Pengyue Li1, Zhen Wang1, Yanke Cheng1, Huichao Wu1, Bing Yang1, Shouying Du2, Yang Lu3.   

Abstract

Panax notoginseng saponins (PNS) constitute the main active components of a traditional Chinese medicine, Panax notoginseng (Burk.) F.H. Chen (Sanqi). To investigate brain distribution of Panax Notoginsenoside R1, Ginsenosides Rg1, Rb1, Re, and Rd, and the integrated PNS in rats, their contents in cortex, striatum, hypothalamus, medulla oblongata, hippocampus and olfactory bulb were simultaneously measured by UPLC-MS/MS. Sample preparation was carried out by the protein precipitation technique with an internal Digoxin standard. The method described here was highly efficient, with short run time, excellent specificity and sensitivity, and successfully applied for pharmacokinetics studies. NGR1, GRg1, GRb1, GRe and GRd from PNS have been detected in all six brain regions studied and quantified accurately. These findings provide more insight for further understanding of the main ways from the nasal cavity to brain as well as the migration of nasally applied drugs into the CNS parenchyma.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain distribution; Integrated pharmacokinetics; Intranasal administration; Panax Notoginseng Saponins; Pharmacokinetics

Mesh:

Substances:

Year:  2014        PMID: 25203723     DOI: 10.1016/j.jchromb.2014.08.034

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  8 in total

Review 1.  Discovery and Current Status of Evaluation System of Bioavailability and Related Pharmaceutical Technologies for Traditional Chinese Medicines--Flos Lonicerae Japonicae--Fructus Forsythiae Herb Couples as an Example.

Authors:  Wei Zhou; Baochang Cai; Jinjun Shan; Shouchuan Wang; Liuqing Di
Journal:  Int J Mol Sci       Date:  2015-12-04       Impact factor: 5.923

2.  Multitarget effects of Korean Red Ginseng in animal model of Parkinson's disease: antiapoptosis, antioxidant, antiinflammation, and maintenance of blood-brain barrier integrity.

Authors:  Jong Hee Choi; Minhee Jang; Seung-Yeol Nah; Seikwan Oh; Ik-Hyun Cho
Journal:  J Ginseng Res       Date:  2018-01-31       Impact factor: 6.060

3.  Notoginsenoside R1 for Organs Ischemia/Reperfusion Injury: A Preclinical Systematic Review.

Authors:  Qiang Tong; Peng-Chong Zhu; Zhuang Zhuang; Li-Hui Deng; Zi-Hao Wang; Hua Zeng; Guo-Qing Zheng; Yan Wang
Journal:  Front Pharmacol       Date:  2019-10-17       Impact factor: 5.810

4.  Ginsenoside Rb1 Attenuates High Glucose-Induced Oxidative Injury via the NAD-PARP-SIRT Axis in Rat Retinal Capillary Endothelial Cells.

Authors:  Chunlan Fan; Qing Ma; Meng Xu; Yuan Qiao; Yi Zhang; Pin Li; Yucong Bi; Minke Tang
Journal:  Int J Mol Sci       Date:  2019-10-05       Impact factor: 5.923

Review 5.  Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases.

Authors:  Hai Liu; Jianqiong Yang; Wanqing Yang; Shaonan Hu; Yali Wu; Bo Zhao; Haiyan Hu; Shouying Du
Journal:  Drug Des Devel Ther       Date:  2020-02-07       Impact factor: 4.162

Review 6.  Phytochemical analysis of Panax species: a review.

Authors:  Yuangui Yang; Zhengcai Ju; Yingbo Yang; Yanhai Zhang; Li Yang; Zhengtao Wang
Journal:  J Ginseng Res       Date:  2020-01-14       Impact factor: 6.060

7.  Protective effects of the notoginsenoside R1 on acute lung injury by regulating the miR-128-2-5p/Tollip signaling pathway in rats with severe acute pancreatitis.

Authors:  Ju He; Ming-Wei Liu; Zhi-Yi Wang; Rong-Jie Shi
Journal:  Innate Immun       Date:  2022-01       Impact factor: 2.680

Review 8.  Ginsenoside and Its Therapeutic Potential for Cognitive Impairment.

Authors:  Hui Feng; Mei Xue; Hao Deng; Shiqi Cheng; Yue Hu; Chunxiang Zhou
Journal:  Biomolecules       Date:  2022-09-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.